Unstable Angina Therapeutics Market Snapshot (2023 to 2033)
Valued at US$ 3.86 billion in 2022, the market for unstable angina therapeutics is foreseen to increase to US$ 4.05 billion in FY 2023, representing a Y-o-Y increase of 4.9%. Over the forecast period ranging from 2023 to 2033, the market is anticipated to gain traction at a CAGR of 5%, reaching an industry value of US$ 6.6 billion. According to a Cleveland Clinic report, approximately 200,000 Americans suffer from unstable angina every year. Unstable angina is more prevalent among older people, men, and those who smoke, have high blood sugar levels, or have hypertension.
The primary factors driving the market growth are an augmentation in the number of patients being treated for unstable angina and the authorization of new therapeutics with high safety and effectiveness. Rivaroxaban, varespladib, and otamixaban are a few instances of new therapeutics that are presently in the late phases of clinical progression. If authorized, these products are predicted to be advertised at high prices. Nevertheless, a low adoption rate of therapeutic strategies in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market.
If there is an artery obstruction or shrinking, the practitioner may suggest invasive surgery like angioplasty, and in severe instances, cardiac bypass surgery. The market for unstable angina therapeutics has tremendous growth potential, owing primarily to a rise in the number of people suffering from cardiac ailments, increased tobacco use, poor dietary habits, and lifestyle changes. Therefore, increasing awareness about lifestyle changes is also predicted to boost market growth.
As per one 2020 article, roughly 18 million individuals in the United States suffer from unstable angina. Furthermore, the Americas are expected to represent the majority of global percutaneous coronary interventions. As percutaneous coronary intervention (PCI) is growing more prevalent in the United States and Canada, that region is expected to be the leader in the unstable angina therapeutics industry in the forthcoming years. Because of the increasing prevalence of cardiovascular diseases, enhanced medical facilities, and increasing disposable income, Asia-Pacific is estimated to accelerate at the fastest pace. The Middle East and Africa market share are predicted to grow due to the significant recurrence of therapeutic intervention in Kuwait, Saudi Arabia, and the UAE.
Aspects such as the soaring prevalence of numerous cardiovascular disorders including Coronary Heart Disease (CHD), myocardial infarction, and strokes, in addition to the growing requirement for minimally invasive surgeries, are contributing to the expansion of the coronary artery bypass graft (CABG) surgery segment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are growing in popularity due to variables such as the growing incidence of pain around the world, as well as an enhancement in the worldwide aging populations. Because of the high adoption rate of effective therapies for unstable angina patients, the hospital segment held the largest market share among end-user segments.
Leading healthcare practitioners in the market are employing a variety of therapeutic and combat strategies. These include a variety of measures such as pipeline research to develop effective drug applicants, in-house therapy sessions, and collaboration with healthcare technology providers to establish advanced therapeutics infrastructures.
Data Points
Key Statistics
Expected Market Value (2023)
US$ 4.05 billion
Anticipated Forecast Value (2033)
US$ 6.6 billion
Projected Growth Rate (2023 to 2033)
5% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Unstable Angina Therapeutics Historical Analysis 2018 to 2022 vs. Future Prospects 2023 to 2033
According to Future Market Insights, unstable angina therapeutics experienced a substantial boost from 2018 to 2022, with a CAGR of 4%. COVID-19 had become a significant public health concern in the historical period. In the past, unsuitable cautions against the usage of NSAID stimulants for COVID-19 patients with a higher likelihood of adverse impacts have been imposed. This caused widespread consternation among patient populations and the healthcare sector. As a result, COVID-19 had a significant impact on the consumption and prescription of various drugs for unstable angina in the global market.
Increasing medical prices will raise the economic strain on uninsured patients over the projected timeframe, causing individuals to migrate to developing countries where surgery costs less. This, in turn, is increasing the need for medical tourism in evolving countries. Among the main determinants predicted to propel the market in emerging economies over the forecast period are the presence of advantages like improved healthcare, lower surgical costs, and superior hospitality.
Prominent Drivers Influencing Market Growth of Unstable Angina Therapeutics
Global Geriatric Population Growth to steer Market Growth
As a result, the growing elderly population around the world is predicted to propel market growth. Based on an Administration on Aging (AoA) report, the number of people aged 65 and older in the United States was about 54.1 million in 2019, accounting for more than 16% of the total population.
There were approximately 30 million women and approximately 24.1 million men among them. By 2040, this population is predicted to account for 21.6% of the total in the United States. As a result, the growing geriatric population is predicted to drive the expansion of the unstable angina therapeutics market in the coming years.
Drugs Authorization by government drives Market Growth
The increasing number of medications approved by government agencies is expected to drive the growth of the unstable angina therapeutics market in the coming decades. Clopidogrel, for instance, is FDA-approved for the medical treatment of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI).
Clopidogrel, when combined with aspirin, has historically been demonstrated to lower the probability of death, reoccurring heart attacks, or stroke in patient populations with unstable angina or a less severe cardiac attack.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Projected to be Faced by the Market?
Low Adoption Rate of Treatment and High Costs to Hinder Market Growth
Nevertheless, a low adoption rate of new treatments in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market. Other attributes like patent expirations and the exorbitant prices of drug development may also impede market growth. For instance, a coronary artery bypass graft surgery costs an average of $54,000 - $148,400 in the United States.
Region-Wise Insights
What Makes North America the Largest Market for Unstable Angina Therapeutics?
Advanced Surgeries and Treatments Options drive the Regional Market Growth
Owing to the evolving guidelines related to patient treatment and management, North America is anticipated to dominate the unstable angina therapeutics market over the coming years. The occurrence of unstable angina is escalating in the United States, with nearly 1 million hospitalized patients having a primary diagnosis of unstable angina every year. As a result, this aspect is anticipated to contribute to industry growth.
Furthermore, North America is predicted to control the whole coronary artery bypass graft surgery market across the forthcoming years, driving future growth even further. For instance, as per data released by the Centers for Disease Control and Prevention in July 2022, 20.1 million Americans aged 20 and adults over the age were impacted by coronary heart disease in 2020. North America accounted for 45% market share in 2022.
Why is Europe Considered a Lucrative Region for the Unstable Angina Therapeutics Market?
Europe is the world's 2nd largest market for Unstable Angina Therapeutics
According to a recent article in Academic Group, Europe is the second largest industry for unstable angina therapeutics. Aspects including the accessibility of research grants, a burgeoning obese and patient citizenry, and the involvement of advanced economies like France, Italy, and Germany in the region all provide favorable backdrops for regional market expansion.
Unstable angina causes over 115,000 acute hospitalizations in the UK each year (200 per 100,000 population), with a substantial male predominance. In Europe, hospitalization rates for unstable angina outnumber those for ST-elevation myocardial infarction1. Before the introduction of modern treatment modalities, 15% of patients with unstable angina proceeded to a severe myocardial infarction, with total in-hospital mortality reaching 5%. Thus these factors are expected to propel the regional market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By End-User, Which Segment is Projected to Lead the Market?
Hospital Segment is Estimated to Hold the Largest Share
The hospital segment led the market in 2022, accounting for 46% of total revenue. Hospitals are commonly considered primary healthcare systems, and the patient population's preference for hospitals for the evaluation and treatment of chronic disorders is fuelling segment growth. Furthermore, the same segment is expected to grow at the fastest rate between 2023 and 2033.
By Treatment, Which Segment is Projected to Lead the Market?
Beta Blockers Segment is Estimated to Hold the Largest Share
The beta blockers segment is anticipated to expand at a CAGR of 4.4% during the projected timeline. Because of technological developments, massive expenditure, higher incidence and occurrence of cardiovascular diseases, and an aging population, the popularity of beta blockers has risen exponentially. Furthermore, the segment will benefit from a rising patient population and a lack of adequate treatment.
The Start-up Ecosystem: How Key Players are making Unstable Angina Therapeutics Easier?
Various start-ups are launching advanced treatment procedures and drugs to drive market growth. For instance,
Laura Niklason, MD, Ph. established Humacyte, Inc in 2004. Humacyte, Company revealed outcomes from the first clinical study of Humacyte's small-diameter (3.5mm) Human Acellular Vessel (HAV) in coronary artery bypass grafting (CABG) at Advanced Therapeutic Approaches Week in January 2022.
Market Competition
Key players in the Unstable Angina Therapeutics market are Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, Ablynx, Saphnix Life Sciences, Copperhead Chemical, Medtronic, Enomark Kinetics, CDH Fine Chemical. Some of the latest developments are below,
In patients with an initial MI or unstable angina pectoris, Bayer Healthcare has launched aspirin, which is prescribed to reduce the combined risk of death and previous MI or unstable angina pectoris.
Praluent® (alirocumab) was approved by the FDA in April 2019 to prevent heart attacks, strokes, and unstable angina that requires hospitalization. Praluent treatment was found to be effective in patients who were already obtaining other lipid-lowering treatments, such as sufficiently acceptable statins.
Report Scope
Report Attribute
Details
Expected Market Value (2023)
US$ 4.05 billion
Anticipated Forecast Value (2033)
US$ 6.6 billion
Projected Growth Rate (2023 to 2033)
5% CAGR
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Treatment
End User
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
Indonesia
Singapore
Thailand
China
Japan
South Korea
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Bayer AG
Sanofi S.A
Anthera Pharmaceuticals
Ablynx
Saphnix Lifesciences
Copperhead Chemical
Medtronic
Enomark
Kinetics
CDH Fine Chemical
Customization
Available Upon Request
Key Segments Profiled in the Unstable Angina Therapeutics Industry Survey
By Treatment:
Percutaneous Coronary Intervention (PCI)
Coronary Artery Bypass Graft Surgery
Supplemental Oxygen Therapy
Drug Class
NSAIDs
Vasodilators
Platelet Aggregation Inhibitors
Anticoagulants
Beta-blockers
By End User:
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Frequently Asked Questions
What is the Projected Size of the Unstable Angina Therapeutics Market by 2033?
The global market size to reach US$ 6.6 million by 2033.
Top Key Players in the Key Unstable Angina Therapeutics Market?
Bayer AG and Kinetics are the top key players.
What is the Growth Potential of the Unstable Angina Therapeutics Market?
The growth potential of the enterprise key management market is 5% through 2033
What Limits the Growth Potential of the Market?
The low adoption of treatment rates is likely to limit market growth.
Which End User Type is Highly Preferred?
The hospital segment is highly preferred in the global market.
Table of Content
1. Executive Summary | Unstable Angina Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Percutaneous Coronary Intervention (PCI)
5.3.2. Coronary Artery Bypass Graft Surgery
5.3.3. Supplemental Oxygen Therapy
5.3.4. Drug Class
5.3.4.1. NSAIDs
5.3.4.2. Vasodilators
5.3.4.3. Platelet Aggregation Inhibitors
5.3.4.4. Anticoagulants
5.3.4.5. Beta-blockers
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Ambulatory Surgical Centres
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End User
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End User
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Bayer AG
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Sanofi S.A
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Anthera Pharmaceuticals Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Ablynx
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Saphnix Lifesciences
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Copperhead Chemical Company
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Medtronic Plc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Enomark
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Cytokinetics Inc.
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. CDH Fine Chemical
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by End User, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by End User, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by End User, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by End User, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Market Attractiveness by End User, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
